David P. Southwell - 02 Feb 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: TCRX
Reported as of: 02 Feb 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Feb 2023, 16:18:26 UTC
Prior SEC filing: 09 Jan 2023
Next SEC filing: 29 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ David P. Southwell

Key filing fact

David P. Southwell filed Form 4 for TScan Therapeutics, Inc. (TCRX) on 06 Feb 2023.

Key facts

This page summarizes David P. Southwell's Form 4 filing for TScan Therapeutics, Inc. (TCRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 06 Feb 2023, 16:18.

Change

Previous filing in this sequence was filed on 09 Jan 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TCRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 02 Feb 2023
Ownership: Direct
Underlying class: Voting Common Stock
Underlying amount: 100,000
Exercise price: $1.81
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.